CN1318373A - Application of Breviscapine in preparing medicine - Google Patents
Application of Breviscapine in preparing medicine Download PDFInfo
- Publication number
- CN1318373A CN1318373A CN 00117476 CN00117476A CN1318373A CN 1318373 A CN1318373 A CN 1318373A CN 00117476 CN00117476 CN 00117476 CN 00117476 A CN00117476 A CN 00117476A CN 1318373 A CN1318373 A CN 1318373A
- Authority
- CN
- China
- Prior art keywords
- breviscapine
- diabetes
- application
- medicine
- complication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Erigeron breviscapine, named 4,5,6-trihydrox flavone-7-O-glucuronic anhydride chemically, can be used to prevent and treat the damage of diabetes to the function of tunica intima and smooth muscle of blood vessels and has obvious preventing and treating effect on various diabetes complications, such as diabetes complicated nephropathy, eye disease, coronary heart disease, etc. It functions by means of blocking intracellular signal transducing system resulting in hyperglycaemia complications.
Description
The present invention relates to the extract-4 of Herba Erigerontis ', 5,6-trihydroxyflavone-7-O-glucuronide has another name called the purposes of breviscapine, relates in particular to the purposes in pharmaceutical field.Its chemical structural formula is:
Molecular formula is C
25H
24O
12, light khaki is Powdered, and molecular weight is 462.21, dissolves in alkaline water.
Herba Erigerontis is the herb of the short booth Herba Erigerontis aceris of Compositae, has activating blood circulation to dissipate blood stasis, the effect of regulating QI to relieve pain.Its treatment cerebrovascular disease of motherland's medical use, evident in efficacy.Breviscapine is that Herba Erigerontis is through the concise effective ingredient of special processes.Existing clinically treat sequela due to cerebral blood supply insufficiency, cerebral thrombosis, the cerebral hemorrhage, high blood viscosity with it.
At present for treatment of diabetes, though effectively control of diabetes patient's blood sugar level of many medicines is arranged clinically, but diabetics is dead mostly in the complication relevant with it, and especially cardiovascular and renal complication have become the diabetics main causes of death.For the treatment of diabetic complications, still lack effective medicine at present clinically.Can in the world complication such as diabetic nephropathy there be certainly effectively medicine (even ACEI) at present in particular.Though synthetic drug aminoguanidine (registered patent) has been developed nearly four more than ten years, because its side effect still fails to be used for clinical at present.Breviscapine is compared with aminoguanidine, and the effect of its prevention complication is stronger than aminoguanidine, and do not have aminoguanidine side effect, so its curative effect is very definite.
The object of the present invention is to provide the new purposes of breviscapine, i.e. new application in pharmacy.
In fact, the present invention relates to the application of breviscapine in the medicine of preparation treatment or prevent diabetes complication.
The present invention relates to breviscapine as the application in the medicine of preparation treatment or diabetes and nephropathy preventing complication.
Relate to breviscapine as the application in the medicine of preparation treatment or prevent diabetes oculopathy complication.
Relate to breviscapine as the application in the medicine of preparation treatment or prevent diabetes coronary heart disease complication.
Also relate to breviscapine as the application in the medicine of preparation treatment or prevent diabetes reproductive system complication.
Also relate to breviscapine as the application in the medicine of preparation treatment or prevent diabetes gastrointestinal complication.
Also relate to breviscapine as the application in the medicine of preparation treatment or prevent diabetes nervous system complication.
Essence for a better understanding of the present invention will illustrate its new purposes in pharmaceutical field with the pharmacological evaluation and the result of breviscapine below.
Fig. 1 is the myocardium vessel ring experiment sketch map of breviscapine;
Fig. 2 is in the body blood vessel experiment of breviscapine, tunica intima dependent vasorelaxation sketch map;
Fig. 3 is in the body blood vessel experiment of breviscapine, vascular smooth muscle stretching reaction sketch map.
1. the acute toxicity testing of small white mouse
A. oral administration: healthy male little of 10 of mouse, body weight 17-24g presses Breviscapinun 10g/kg
It is dead that gavage had no in three days.
B. drug administration by injection: 10 of healthy male white mouses, body weight 17-24g dissolves Breviscapinun
Rear drug administration by injection calculates by simplifying probit method, records
LD50(ⅳ)=1300+160mg/kg。
2. the long term toxicity test of big white mouse
30 of Wistar male white rats, body weight 200-250g is divided into 3 groups, 10 every group. Lamp
The small cup florigen by 1g/kg, 0.5g/kg, 0.1g/kg dosage respectively gavage detect after 3 months and learn,
Hepatic and renal function, surrounding hemogram, behavior, defecation routine are not all had obvious influence, to the heart, liver,
The pathological examination of vitals such as lung is also no abnormal.
3. myocardium vessel ring experiment
As shown in Figure 1, in the tunica intima functional experiment: Control, expression matched group.Diabetic，
The expression diabetic groups.EB+treated, expression diabetes+breviscapine treatment group.* with diabetes
Group is compared.
The Wistar male rat, body weight 200-250g, the disposable abdomen of chain urine rhzomorph (65mg/kg)
The chamber injection.Injection 1 week of back, get one of tail blood, judge that with the Bao Lingman blood glucose meter its hyperglycemia is (right
According to 5.0+0.5mM, diabetes 22+5mM).Diabetic groups is further divided into: diabetic groups, glycosuria
Disease+breviscapine group.In the 2nd, 6 weeks of experiment, the rat broken end is got aortic annulus and is advanced respectively
The row laboratory observation.The result: in the 2nd week of experiment, under the phyenlephrinium preshrinking, Ach's
Stretching reaction is when low concentration, and diabetic groups obviously weakens, but maximum stretching reaction compared with the control
There is not significant change.When the 6th week, the concentration dependent inner membrance diastole of diabetic groups acetylcholine
Response curve all obviously weakens compared with the control in each concentration point, and maximum stretching reaction has reduced approximately
60%[10uM Ach, diabetic groups 57.4 ± 14.4% (n=6) vs matched group 0% (n=6),
P＜0.001], yet in breviscapine treatment group, though when the acetylcholine low concentration, still subtract to some extent
A little less than, but maximum stretching reaction is approaching with contrast, compares the stretching reaction of acetylcholine with diabetic groups
All obviously increase.[0.01 and 0.03uM Ach; Breviscapine treatment group 80.5 ± 4.2% Hes
± 7.3% 58.8 (n=6) vs matched group 45.8 ± 9.2%and 20.1 ± 4.1% (n=6),
p＜0.01.]。At body blood vessel experiment A, as shown in Figure 2, Control represents matched group, DM represents diabetic groups, BT represents breviscapine treatment group.Tunica intima dependent vasorelaxation: 50 of Wistar male rats, body weight 200-250g, the injection of chain urine rhzomorph (65mg/kg) disposable celiac.Injection 1 week of back, get one of tail blood, judge its hyperglycemia (contrast 5.0+0.5mM, diabetes 20+3.5mM) with the Bao Lingman blood glucose meter.Diabetic groups is further divided into: diabetic groups, diabetes+breviscapine group.In the 12 week, row common carotid artery and femoral venous catheter behind the rat anesthesia are pressed the acetylcholine that 0.5ml/kg injects variable concentrations, observe the variation of blood pressure.Found that: the acetylcholine of 0.001uM can cause the blood pressure drops of normal rat, and the acetylcholine of 0.1uM just can cause the blood pressure drops of diabetes rat, at the diabetes rat of taking the 0.1g/kg breviscapine, the acetylcholine of 0.001uM also can cause the blood pressure drops of diabetes rat.Decline curve is very approaching in diabetic groups of taking breviscapine and normal control.B, as shown in Figure 3, Control represents matched group, and DM represents diabetic groups, and BT represents breviscapine treatment group.The vascular smooth muscle stretching reaction: other condition is the same.In the 12 week, row common carotid artery and femoral venous catheter behind the rat anesthesia are pressed the nitre spectrum sodium that 0.5ml/kg injects variable concentrations, observe the variation of blood pressure.Found that: the nitre spectrum sodium of 0.001uM can cause the blood pressure drops of normal rat, yet, compose sodium at the nitre of diabetic groups 10uM and just can cause blood pressure drops.Taking the diabetes rat of breviscapine, the nitre spectrum sodium of 0.001uM also can cause the blood pressure drops of diabetes rat.5. biochemical indicator measurement result
Table-in the 12 week, each organizes biochemical indicator result (n=8, x ± sd).* compare with diabetic groups.
Can illustrate from above result and the invention has the advantages that: (1) the present invention to compound known-4 ', 5,6-trihydroxyflavone-7-O-glucuronide-oil lamp
| Blood NAG enzyme (IU/L) | Serum creatinine (umol/L) | Urine amount (ml) | Urine protein (g/L) | Crystalline lens AR (U/mg/min) | |
| Matched group | 106.3±18.5 | ?61.2±11.5 | ?6±2.7 | ?13.4±5.1 | ?24.2±13.8 |
| Diabetic groups | 200±19.6 | ?85.4±11.8 | ?50.6±14.2 | ?34.4±6.4 | ?92.4±22.3 |
| The breviscapine group | 124±17.2 * | ?54.0±46.3 * | ?19.5±9.3 * | ?17.2±8.7 * | ?42.5±15.4 |
| The P value | ＜0.01 | ?＜0.05 | ?＜0.05 | ?＜0.01 | ?＜0.01 |
Florigen has been excavated new medical application, has opened up a new application.(2) of the present invention 4 ', 5,6-trihydroxyflavone-7-O-glucuronide raw material sources are abundant, can do
Become peroral dosage form, injection type, tablet etc., easy to use.When (3) medicine that is mixed with of material of the present invention has remarkable treatment and prevent diabetes: a. tunica intima
The effect of functional lesion.B. the effect of vascular smooth muscle functional lesion.Glomerule when (4) medicine that is mixed with of material of the present invention has remarkable treatment and prevent diabetes, kidney are little
The effect of pipe infringement, because the significantly rising of serum creatinine, blood NAG enzyme during prevent diabetes,
Significantly reduce the urine amount and the urine protein of diabetes rat, showing has significant control to diabetic nephropathy
Effect.(5) because the medicine that material of the present invention is mixed with has crystalline aldose reductase when significantly preventing and treating diabetes
The effect that raises can be used for treating the diabetic ophthalmopathy complication.(6) aldose reductase raises when significantly preventing and treating diabetes because the medicine that material of the present invention is mixed with has
Effect, can be used for preventing and treating the diabetes nerve complication.(7) show through clinical trial: the injection that material of the present invention is mixed with, tablet take effect rapidly, curative effect
Significantly.In diabetic nephropathy patient (5 example), use the Drug therapy that material of the present invention is mixed with
(10mg/kg) week, found that: urine protein reduces rapidly.Studies show that through the kidney biopsy,
The treatment group obvious diabetic nephropathy not only do not occur and changes, and has stoped diabetic nephropathy sick in early days
The generation of change-nephron hypertrophy (hypertrophy).In diabetic eye patient (7 example), should
In two weeks of Drug therapy (12mg/kg) with material of the present invention is mixed with, found that: treatment
The group vision on average improves 25%, and ophthalmofundoscopy finds that the optical fundus circulation has clear improvement.(8) medicine that is mixed with of material of the present invention in biggest advantage aspect the control diabetic complications is:
Do not influence under the situation of blood sugar level, significantly treatment and prevent diabetes complication.Its action target spot
Be to block signal transducting system in the cell after the hyperglycemia.Therefore, can be used for preventing and treating diabetes
Each the system's complication that causes.Share with antidiabetic drug, can significantly treat diabetes, obviously prolong and suffer from
Person's life.
Embodiment of various details, but content of the present invention is not limited to this fully.
Embodiment
Adopt Compositae Herba Erigerontis aceris platymiscium Herba Erigerontis (Erigeron breviscapus (Vant) Hand-Mazz) whole plant 10kg, by commonsense method extract 4 ', 5,6-trihydroxyflavone-7-O-glucuronide is prepared into tablet by the existing method of those skilled in the art.Wherein the content of tablet can strengthen or minimizing by actual needs.
Claims (7)
1. the application of breviscapine in the medicine of preparation treatment or prevent diabetes complication.
2. the application of breviscapine in the medicine of preparation treatment or diabetes and nephropathy preventing.
3. the application of breviscapine in the medicine of preparation treatment or prevent diabetes oculopathy.
4. the application of breviscapine in the medicine of preparation treatment or prevent diabetes coronary heart disease.
5. the application of breviscapine in the medicine of preparation treatment or prevent diabetes reproductive system complication.
6. the application of breviscapine in the medicine of preparation treatment or prevent diabetes gastrointestinal complication.
7. the application of breviscapine in the medicine of preparation treatment or prevent diabetes nervous system complication.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001174762A CN1147303C (en) | 2000-10-09 | 2000-10-09 | Application of Breviscapine in preparing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001174762A CN1147303C (en) | 2000-10-09 | 2000-10-09 | Application of Breviscapine in preparing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1318373A true CN1318373A (en) | 2001-10-24 |
| CN1147303C CN1147303C (en) | 2004-04-28 |
Family
ID=4586841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001174762A Expired - Fee Related CN1147303C (en) | 2000-10-09 | 2000-10-09 | Application of Breviscapine in preparing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1147303C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089478A1 (en) * | 2005-02-22 | 2006-08-31 | Guanzheng Shi | The use of isoscutellarin for the manufacture of medicine |
| CN100333741C (en) * | 2005-07-11 | 2007-08-29 | 中山大学中山医学院科技开发中心 | Medicine for preventing and treating diabets and kidney disease and preparing method |
| CN100344290C (en) * | 2002-11-29 | 2007-10-24 | 北京天衡药物研究院 | Breviscapine dispersing tablet and its prepn |
| CN102512435A (en) * | 2012-01-05 | 2012-06-27 | 昆明制药集团股份有限公司 | Application of 5,6,4'-trihydroxyl flavone-7-O-beta-D-glucuronide methyl ester and medicinal composition as well as preparation thereof |
| CN102875620A (en) * | 2012-10-16 | 2013-01-16 | 昆明龙津药业股份有限公司 | New derivatives of myricetin and application of derivatives to medicine preparation |
| CN103893196A (en) * | 2014-04-02 | 2014-07-02 | 闫莹 | Medical application of sedoisoprosan and pharmaceutical composition of sedoisoprosan |
| CN113304161A (en) * | 2021-05-27 | 2021-08-27 | 昆明医科大学 | Application of scutellarin in preparation of drug for stent coating |
-
2000
- 2000-10-09 CN CNB001174762A patent/CN1147303C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344290C (en) * | 2002-11-29 | 2007-10-24 | 北京天衡药物研究院 | Breviscapine dispersing tablet and its prepn |
| WO2006089478A1 (en) * | 2005-02-22 | 2006-08-31 | Guanzheng Shi | The use of isoscutellarin for the manufacture of medicine |
| CN100333741C (en) * | 2005-07-11 | 2007-08-29 | 中山大学中山医学院科技开发中心 | Medicine for preventing and treating diabets and kidney disease and preparing method |
| CN102512435A (en) * | 2012-01-05 | 2012-06-27 | 昆明制药集团股份有限公司 | Application of 5,6,4'-trihydroxyl flavone-7-O-beta-D-glucuronide methyl ester and medicinal composition as well as preparation thereof |
| CN102512435B (en) * | 2012-01-05 | 2014-02-05 | 昆明制药集团股份有限公司 | Application of scutellarin methyl ester and medicinal composition as well as preparation thereof |
| CN102875620A (en) * | 2012-10-16 | 2013-01-16 | 昆明龙津药业股份有限公司 | New derivatives of myricetin and application of derivatives to medicine preparation |
| CN102875620B (en) * | 2012-10-16 | 2015-02-04 | 昆明龙津药业股份有限公司 | New derivatives of myricetin and application of derivatives to medicine preparation |
| CN103893196A (en) * | 2014-04-02 | 2014-07-02 | 闫莹 | Medical application of sedoisoprosan and pharmaceutical composition of sedoisoprosan |
| CN113304161A (en) * | 2021-05-27 | 2021-08-27 | 昆明医科大学 | Application of scutellarin in preparation of drug for stent coating |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1147303C (en) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1814166A (en) | Pulse-promoting powder injecta and preparing method | |
| CN1095472C (en) | Folica acid-polysaccharide composite and its preparation and medical composition with the composite as active component | |
| CN1147303C (en) | Application of Breviscapine in preparing medicine | |
| CN100435803C (en) | Use of taurine in preparation of injection containing puerarin | |
| CN1679924A (en) | Compound insulin energy mistura preparation and use thereof | |
| CN101040906A (en) | Injection for treating cardiovascular or cerebrovascular disease and the preparing method and the quality control method | |
| CN101574343A (en) | Medicament composition for treating sugar diabetes | |
| CN1086289C (en) | Medicine for treating diabetes and nephrosis containing rheinic acid | |
| CN1169839C (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN1534010A (en) | Water soluble extract of red sage root and its preeparation method and use | |
| CN1081465C (en) | Rhodiola rosea injection for treating angina pectoris of coronary heart disease | |
| CN1872852A (en) | Derivative of berberine, and prepartion method, composition of medication, and application | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1296082C (en) | Medication and health food in use for lowering blood sugar, improving function of intestinal tract and reducing platelet aggergation | |
| CN1689579A (en) | Application of burdock glycoside or its aglycon in preparation of medicine for treating diabetes or its complications | |
| CN1778309A (en) | Use of arctiin and its aglycon in preparation of medicines for diabetes and nephrosis | |
| CN1857297A (en) | Medicine composition for treating microcirculation dysfunction and its preparing method | |
| CN110448562A (en) | Application of the lupenone in preparation treatment renal damage drug | |
| CN1839869A (en) | Use of molo glycoside in alpha-glucosaccharase inhibitor | |
| CN1449762A (en) | Application of scutellarin composition in preparing medicine for preventing and treating diabetes complication | |
| CN1265805C (en) | Chinese medicine oral preparation for lonering blood sugar and its preparation method | |
| CN1491664A (en) | Composite medicinal preparation containing inosine matters | |
| CN1263849C (en) | Dual water phase extracting system and process for separating and purifying alpha-amylase inhibitor by said system | |
| CN1224390C (en) | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver | |
| CN1269488C (en) | Pharmaceutical composition capable of resisting cancer and easing pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040428 Termination date: 20131009 |